Approval · Notice of Compliance 19415 · 2017
NEUPOGEN: Notice of Compliance 19415
Issued June 15, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19415
- Date
- June 15, 2017
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additional manufacturing facility
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NEUPOGEN | Not yet assigned | — |
Medicinal ingredients
- FILGRASTIM (R-METHUG-CSF) 300 MCG per ML
- FILGRASTIM (R-METHUG-CSF) 600 MCG per ML